In the Phase 2 obesity trial it produced about 24% weight loss at 12 mg over 48 weeks, the most of any drug in the class, and it cut liver fat by 86% in the people who started with fatty liver. In the 80-week Phase 3 obesity trial of 2,300 adults with an average BMI of 40, 12 mg produced 28% weight loss and 9 mg reached 26%
A study published in the National Library of Congress examined the effect of topical BPC-157 on alkali burnsamong the most difficult wounds to treat due to deep tissue penetration
[1] It is investigated for its potential role in nitric oxide pathway modulation, growth factor signaling, and extracellular matrix remodeling
Always follow your healthcare providers instructions, ensure sterility during use, and be aware of potential side effects, particularly if youre allergic to preservatives or treating infants
This product is not intended for diagnostic, therapeutic, medical, or veterinary use under any circumstances